文化大學機構典藏 CCUR:Item 987654321/22949
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 46965/50831 (92%)
造访人次 : 12671145      在线人数 : 826
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于CCUR ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://irlib.pccu.edu.tw/handle/987654321/22949


    题名: The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease
    作者: Chiang, Ming-Chang
    Chern, Yijuang
    Juo, Chiun-Gung
    贡献者: 生物科技研究所
    关键词: NEURODEGENERATIVE DISEASES
    ACTIVATED-RECEPTOR-GAMMA
    UREA CYCLE DEFICIENCY
    PEROXISOME-PROLIFERATOR
    PPAR-GAMMA
    MUTANT HUNTINGTIN
    MOUSE MODEL
    C/EBP-ALPHA
    MITOCHONDRIAL DYSFUNCTION
    GENE-EXPRESSION
    日期: 2011-09
    上传时间: 2012-09-07 14:49:40 (UTC+8)
    摘要: Huntington's Disease (HD) is an autosomal dominant neurodegenerative disease caused by a CAG trinucleotide expansion in the Huntingtin (Htt) gene. The resultant mutant Htt protein (mHtt) forms aggregates in the brain and several peripheral tissues (e.g., the liver), and causes devastating widespread pathology. Since aggregates of mHtt have been found in the liver, defects in liver function might contribute to peripheral abnormalities in HD mice. We previously reported that two crucial transcription factors PPAR gamma (peroxisome proliferator-activated receptor-gamma) and C/EBP alpha (CCAAT/enhancer-binding protein alpha) are potential therapeutic targets of HD. We herein demonstrate that the transcript level of PPAR gamma was markedly downregulated in the livers of a transgenic mouse model of HD (R6/2). Treatment of R6/2 mice with an agonist of PPAR gamma (thiazolidinedione, TZD) normalized the reduced PPAR gamma transcript. By reducing Htt aggregates and thereby ameliorating the recruitment of PPAR gamma into Htt aggregates, TZD treatment also elevated the availability of the PPAR gamma level and subsequently normalized the expression of its downstream genes [including PGC-1 alpha (PPAR coactivator-1 alpha) and several mitochondrial genes] and C/EBP alpha in the liver. The aforementioned protective effects appeared to be exerted by a direct activation of the PPAR gamma agonist (rosiglitazone) because rosiglitazone reduced mHtt aggregates and rescued energy deficiency in a hepatoma cell line (HepG2). These findings show that the impairment of PPAR gamma contributes to the liver dysfunction observed in HD. Treatment with PPAR gamma agents (TZD and rosiglitazone) enhanced the function of PPAR gamma, and might lead to therapeutic benefits. (C) 2011 Elsevier B.V. All rights reserved.
    關聯: Source: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE Volume: 1812 Issue: 9 Pages: 1111-1120
    显示于类别:[生物科技研究所 ] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML514检视/开启


    检视Licence
    检视Licence

    在CCUR中所有的数据项都受到原著作权保护.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈